Expert Interviews

CD388, an investigational nonvaccine antiviral, demonstrated efficacy up to 76% against influenza in a cohort of more than 5000 healthy, unvaccinated adults.

Panelists discuss the vital role of primary care providers in early skin cancer detection, highlighting the need for improved diagnostic confidence, integration of artificial intelligence (AI) tools, and efficient workflows to overcome time and resource constraints, ultimately aiming to reduce delays and improve patient outcomes.

Atopic dermatitis is not just "another rash on the schedule. It could be the reason that patient doesn't leave the house," Shahriari says.

RAD 2025: Multidisciplinary collaboration at disease-specific meetings drives clinical and therapeutic progress in AD, Dr Yu told Patient Care.

Dermatologists aren't trained in mental health but once in practice they need to have a deep appreciation for the emotional impact of diseases like AD and a low bar for mental health referral.

At RAD 2025, Dr Yu shared hopes for more real-world data and targeted treatment approaches for chronic hand eczema.

RAD 2025: Yale dermatologist Mona Shahriari, MD, urged primary care clinicians to refer patients with AD who don't improve to prevent cumulative emotional burden.

RAD 2025: Expert insights on the psychosocial burden of AD, flexible dosing, and cross-specialty collaboration in pediatric care.

RAD 2025: Johann Gudjonsson, MD, PhD, on investigational AD treatments, including anti–IL-31 receptor antibodies, anti–IL-13 treatments, IL-4 receptor blockers, JAK inhibitors, and new topical agents.

RAD 2025: Brad Glick, DO, MPH, discusses the intensity of TSW symptoms and cautions against assuming there is mental health disturbance at work.

Johann Gudjonsson, MD, discusses how OX-40/OX-40L signaling drives immune activation in AD and its emerging role as a genetic and therapeutic target.

The literature on topical steroid withdrawal syndrome is scant, Glick says; we're learning more about it, but we need more research to help our patients.

RAD 2025: Peter Lio, MD, discussed the benefits of disease-specific meetings, the evolving AD landscape, and why continuity across sessions enhances clinician education.

RAD 2025: Glick spoke to Patient Care about the similarities between TSW and a flare of atopic dermatitis as well as specific signs now being identified d as characteristic.

The American College of Lifestyle Medicine recently published "that guideline," and lead author Richard Rosenfeld, MD, MPH, MBA, says the timing was right.

At RAD 2025, pediatric dermatologist Elizabeth Swanson, MD, discussed the value of focused AD education and anticipated label expansions for several treatments.

RAD 2025: Chovatiya toplines shifts in dosing strategies for topical, oral, and injectable AD therapy observed in both clinical trials and clinical practice.

RAD 2025. Peter Lio, MD, shares details from his presentation on shared decision making when treating children with atopic dermatitis.

RAD 2025: Chovatiya spoke at RAD about the need to better understand how treatments for AD are being used in the real world, after symptoms subside and skin signs clear.

RAD 2025: Jiade Yu, MD, discussed chronic hand eczema as a distinct condition from AD, highlighting its clinical burden and emerging treatments, such as delgocitinib.

A panelist discusses how shared decision-making between healthcare providers and patients should guide epinephrine device selection, with two real-world case studies demonstrating successful Neffy use in treating anaphylaxis with rapid symptom resolution.

A panelist discusses how Neffy addresses unmet needs through superior temperature stability (tolerating up to 122°F for 3-4 days), extended shelf life (24-30 months), and needle-free administration that eliminates injection-related complications.

A panelist discusses how real-world studies in Japan showed Neffy successfully treated grade 2 anaphylaxis symptoms in pediatric patients with a median resolution time of 16 minutes and minimal adverse effects.

A panelist discusses how FDA bracketing studies demonstrated that Neffy's pharmacokinetics and pharmacodynamics fall within the established safety and efficacy range of existing epinephrine auto-injectors, with rapid onset within one minute.

A panelist discusses how Neffy represents a novel intranasal epinephrine delivery system using three FDA-approved components: epinephrine, Intravail absorption enhancer, and a proven nasal spray device already used in other medications.

A panelist discusses how multiple barriers prevent timely epinephrine use, including patient reluctance to use auto-injectors, lack of device availability, uncertainty about administration timing, and cost concerns, leading to widespread underuse.

A panelist discusses how early epinephrine administration significantly reduces severe complications, prevents progression to life-threatening stages, and decreases the need for additional medical interventions like hospitalization or multiple doses.

A panelist discusses how epinephrine is the first and only evidence-based first-line treatment for anaphylaxis, working through alpha and beta adrenergic receptors to rapidly reverse life-threatening symptoms unlike slower-acting antihistamines.

A panelist discusses how anaphylaxis affects approximately 40 million people in the United States with severe systemic reactions involving multiple organ systems, leading to over 500,000 emergency room visits annually.